Luciano J. Costa

16.3k total citations · 1 hit paper
256 papers, 4.8k citations indexed

About

Luciano J. Costa is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Luciano J. Costa has authored 256 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Hematology, 117 papers in Oncology and 96 papers in Molecular Biology. Recurrent topics in Luciano J. Costa's work include Multiple Myeloma Research and Treatments (155 papers), Protein Degradation and Inhibitors (67 papers) and Chronic Lymphocytic Leukemia Research (39 papers). Luciano J. Costa is often cited by papers focused on Multiple Myeloma Research and Treatments (155 papers), Protein Degradation and Inhibitors (67 papers) and Chronic Lymphocytic Leukemia Research (39 papers). Luciano J. Costa collaborates with scholars based in United States, Spain and Brazil. Luciano J. Costa's co-authors include Kelly Godby, Shaji Kumar, Parameswaran Hari, Harry A. Drabkin, Elizabeth E. Brown, Robert K. Stuart, Ilene Brill, James Omel, Susan Bal and Steven M. Devine and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Luciano J. Costa

232 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2022 350 citations Monique C. Minnema, Niels W.C.J. van de Donk et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luciano J. Costa United States	35	3.2k	2.4k	1.9k	651	619	256	4.8k
Amrita Krishnan United States	35	2.9k 0.9×	2.8k 1.2×	2.2k 1.1×	721 1.1×	745 1.2×	198	5.6k
Stefan Knop Germany	33	1.9k 0.6×	2.1k 0.9×	1.9k 1.0×	641 1.0×	396 0.6×	152	4.4k
Mohamad A. Hussein United States	33	2.5k 0.8×	2.2k 0.9×	2.2k 1.1×	592 0.9×	916 1.5×	129	4.8k
Keith Stockerl‐Goldstein United States	36	3.3k 1.0×	1.8k 0.8×	1.7k 0.9×	1.4k 2.2×	671 1.1×	200	5.2k
Natalie S. Callander United States	41	4.0k 1.2×	2.8k 1.2×	3.2k 1.7×	573 0.9×	716 1.2×	199	5.9k
Katja Weisel Germany	33	4.3k 1.3×	3.0k 1.2×	3.2k 1.7×	634 1.0×	711 1.1×	335	5.7k
Laura Rosiñol Spain	41	5.1k 1.6×	2.9k 1.2×	3.7k 1.9×	486 0.7×	846 1.4×	219	6.2k
Monique C. Minnema Netherlands	39	2.9k 0.9×	2.1k 0.9×	1.8k 1.0×	1.0k 1.5×	1.6k 2.6×	229	5.6k
Chatchada Karanes United States	30	3.0k 0.9×	1.6k 0.7×	1.0k 0.5×	883 1.4×	695 1.1×	148	4.5k
Martin Kaiser United Kingdom	39	2.9k 0.9×	2.0k 0.8×	3.0k 1.6×	326 0.5×	403 0.7×	208	4.8k

Countries citing papers authored by Luciano J. Costa

Since Specialization

Citations

This map shows the geographic impact of Luciano J. Costa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luciano J. Costa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luciano J. Costa more than expected).

Fields of papers citing papers by Luciano J. Costa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luciano J. Costa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luciano J. Costa. The network helps show where Luciano J. Costa may publish in the future.

Co-authorship network of co-authors of Luciano J. Costa

This figure shows the co-authorship network connecting the top 25 collaborators of Luciano J. Costa. A scholar is included among the top collaborators of Luciano J. Costa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luciano J. Costa. Luciano J. Costa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Costa, Luciano J., Katja Weisel, Surbhi Sidana, et al.. (2024). Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.. Journal of Clinical Oncology. 42(16_suppl). 7504–7504. 2 indexed citations

Costa, Luciano J., Katja Weisel, Surbhi Sidana, et al.. (2024). MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis. Clinical Lymphoma Myeloma & Leukemia. 24. S569–S570.

White, Joshua S., Rajshekhar Chakraborty, Luciano J. Costa, et al.. (2024). Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria. Leukemia & lymphoma. 65(14). 2163–2172. 1 indexed citations

Costa, Luciano J., et al.. (2024). P-036 BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy. Clinical Lymphoma Myeloma & Leukemia. 24. S61–S62.

Costa, Luciano J., Eva Medvedova, Binod Dhakal, et al.. (2024). Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation. Blood. 144(Supplement 1). 363–363. 1 indexed citations

Costa, Luciano J., Thomas W. LeBlanc, Hans Tesch, et al.. (2024). Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncology. 20(17). 1175–1189. 6 indexed citations

Costa, Luciano J., Nizar J. Bahlis, Saad Z. Usmani, et al.. (2024). Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235. 1 indexed citations

Morillo, Daniel, Carmen Martínez Chamorro, Luciano J. Costa, et al.. (2024). P-058 Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S74–S75. 1 indexed citations

Mateos, María‐Victoria, Sikander Ailawadhi, Luciano J. Costa, et al.. (2023). Global disparities in patients with multiple myeloma: a rapid evidence assessment. Blood Cancer Journal. 13(1). 109–109. 10 indexed citations

10.

Bahlis, Nizar J., Luciano J. Costa, Thierry Façon, et al.. (2023). Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH). PubMed. 5(2-3). 112–121. 1 indexed citations

11.

Bal, Susan & Luciano J. Costa. (2023). Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma. British Journal of Haematology. 204(2). 449–454. 2 indexed citations

12.

Silbermann, Rebecca, Timothy M. Schmidt, Susan Bal, et al.. (2023). Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation. SHILAP Revista de lepidopterología. 4(3). 775–778. 2 indexed citations

13.

Wong, Sandy W., Habib Hamidi, Luciano J. Costa, et al.. (2023). Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. Frontiers in Immunology. 14. 1085893–1085893. 3 indexed citations

14.

Noubouossie, Denis F., et al.. (2022). Passenger Lymphocyte Syndrome and Autoimmune Hypothyroidism Following Hematopoietic Stem Cell Transplantation. SHILAP Revista de lepidopterología. 2022. 1–6.

15.

Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 40(25). 2901–2912. 146 indexed citations

16.

Chhabra, Saurabh, Rebecca Silbermann, Bhagirathbhai Dholaria, et al.. (2021). Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S70–S70.

17.

Clé, Diego V., Alexandre V. Hirayama, Alvaro J. Alencar, et al.. (2021). Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients. Hematology Transfusion and Cell Therapy. 43. S3–S12. 3 indexed citations

18.

Costa, Luciano J., Sandy W. Wong, Arancha Bermúdez, et al.. (2019). First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Blood. 134(Supplement_1). 143–143. 132 indexed citations

19.

Bhella, Sita, Navneet S. Majhail, Luciano J. Costa, et al.. (2018). Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 24(5). 909–913. 31 indexed citations

20.

Voorhees, Peter M., Luciano J. Costa, Brandi Reeves, et al.. (2017). Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT). Blood. 130. 1879–1879. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact